Lamotrigine Extended-Release Tablets

**Type of Posting**
Notice of Intent to Revise

**Posting Date**
25–Jan–2019

**Targeted Official Date**
To Be Determined, Revision Bulletin

**Expert Committee**
Chemical Medicines Monographs 4

In accordance with section 7.04 (c) of the 2015–2020 Rules and Procedures of the Council of Experts and the Pending Monograph Guideline, this is to provide notice that the Chemical Medicines Monographs 4 Expert Committee intends to revise the Lamotrigine Extended-Release Tablets monograph.

Based on the supporting data received from a manufacturer awaiting FDA approval, the Expert Committee proposes to add *Dissolution Test 8* to the monograph.

- *Dissolution Test 8* was validated using a Waters Corporation Symmetry Shield RP8 brand of L7 column. The typical retention time for lamotrigine is about 6.7 min.

The revision also necessitates a change in the table numbering in the test for *Organic Impurities*.

The proposed revision is contingent on FDA approval of a product that meets the proposed monograph specifications. The proposed revision will be published as a Revision Bulletin and an official date will be assigned to coincide as closely as possible with the FDA approval of the associated product.

See below for additional information about the proposed text.1

Should you have any questions, please contact Ren-Hwa Yeh, Senior Scientific Liaison to the Chemical Medicines Monographs 4 Expert Committee (301-998-6818 or rhy@usp.org).

---

1 This text is not the official version of a *USP–NF* monograph and may not reflect the full and accurate contents of the currently official monograph. Please refer to the current edition of the *USP–NF* for official text.

USP provides this text to indicate changes that we anticipate will be made official once the product subject to this proposed revision under the Pending Monograph Program receives FDA approval. Once FDA approval is granted for the associated revision request, a Revision Bulletin will be posted that will include the changes indicated herein, as well as any changes indicated in the product’s final approval, combined with the text of the monograph as effective on the date of approval. Any revisions made to a monograph under the Pending Monograph Program that are posted without prior publication for comment in the *Pharmacopeial Forum* must also meet the requirements outlined in the *USP Guideline on Use of Accelerated Processes for Revisions to the USP–NF*. 
Lamotrigine Extended-Release Tablets

**DEFINITION**
Lamotrigine Extended-Release Tablets contain NLT 90.0% and NMT 110.0% of the labeled amount of lamotrigine (C_{9}H_{7}Cl_{2}N_{2}).

**IDENTIFICATION**
• A. The retention time of the major peak of the Sample solution corresponds to that of the Standard solution, as obtained in the Assay.

**ASSAY**
• **PROCEDURE**
Mobile phase: Acetonitrile, water, and trifluoroacetic acid (25:75:0.05)
Diluent: Acetonitrile, methanol, and water (10:20:70)
Standard solution: 0.25 mg/mL of USP Lamotrigine RS in Diluent. Sonication may be used to aid dissolution.
Sample stock solution: Nominally 0.2–0.3 mg/mL of lamotrigine in 0.1 M hydrochloric acid from a suitable solution obtained in the Sample preparation as follows. Transfer NLT 5 Tablets to a suitable volumetric flask containing 10% of the flask volume of methanol. Sonicate for 10 min. Add 30% acetonitrile. Allow the Tablets to disperse. Add 20% of the flask volume of 0.1 M hydrochloric acid. Sonicate for 25 min or until a fine, even dispersion is obtained. Allow to cool to room temperature. Dilute with 0.1 M hydrochloric acid to volume. Pass a portion of the solution through a nylon filter of 0.45-µm pore size and use the filtrate.
Sample solution: Nominally 0.2–0.3 mg/mL of lamotrigine in 0.1 M hydrochloric acid from a suitable solution obtained in the Sample preparation as follows. Transfer NLT 5 Tablets to a suitable volumetric flask containing 10% of the flask volume of methanol. Sonicate for 10 min. Add 30% acetonitrile. Allow the Tablets to disperse. Add 20% of the flask volume of 0.1 M hydrochloric acid. Sonicate for 25 min or until a fine, even dispersion is obtained. Allow to cool to room temperature. Dilute with 0.1 M hydrochloric acid to volume. Pass a portion of the solution through a nylon filter of 0.45-µm pore size and use the filtrate.

**Chromatographic system**
(See Chromatography (621), System Suitability.)
Mode: LC
Detector: UV 270 nm
Column: 4.6-mm × 15-cm; 3-µm packing L1
Column temperature: 40°C
Flow rate: 1 mL/min
Injection volume: 5 µL
Run time: NLT 8 times the retention time of lamotrigine

**System suitability**
Sample: Standard solution
Suitability requirements:
Tailing factor: NMT 2.0
Relative standard deviation: NMT 1.5%

**Analysis**
Samples: Standard solution and Sample solution
Calculate the percentage of the labeled amount (Q) of lamotrigine (C_{9}H_{7}Cl_{2}N_{2}) dissolved at each time point i:

$$\text{Result} = \left( \frac{Q_i}{Q_s} \right) \times \frac{C_i}{C_s} \times 100$$

where:
- $Q_i$ = nominal concentration of lamotrigine in the Sample solution (mg/mL)
- $Q_s$ = nominal concentration of lamotrigine in the Standard solution (mg/mL)
- $C_i$ = concentration of USP Lamotrigine RS in the Sample solution (mg/mL)
- $C_s$ = concentration of the Standard solution (mg/mL)
- $V$ = volume of Medium, 900 mL
- $D$ = dilution factor if needed
- $L$ = label claim (mg/Tablet)

**Acceptance criteria:** 90.0%–110.0%

**PERFORMANCE TESTS**

**Change to read:**

• **Dissolution** (711)

**Test 1**
Medium 1: 0.01 M hydrochloric acid; 700 mL

Medium 2: 7.8 g of tribasic sodium phosphate, and 22.5 g of sodium dodecyl sulfate in 1 L of water. This solution has a pH of about 12.

**Apparatus 2:** 50 rpm with sinkers (see Dissolution (711), Figure 2a)

**Times**
For Tablets labeled to contain 25 or 50 mg: 2, 7, 15 h
For Tablets labeled to contain 100, 200, or 250 mg: 2, 5, 12 h
For Tablets labeled to contain 300 mg: 2, 6, 13 h

**Procedure:** Run the test with Medium 1 for 2 h. Add 200 mL of Medium 2, preheated at 37°C. Within 5 min of the addition of Medium 2, withdraw the sample for the 2-h time point. Continue the testing by drawing samples at the time points specified in Table 1, Table 2, or Table 3, depending on the label claim.

**Diluent:** Medium 1 and Medium 2 (70:20)

**Standard solution:** Pass a suitable portion of the solution under test through a suitable filter of 0.45-µm pore size. Dilute with Diluent if necessary.

**Blank:** Diluent

**Instrumental conditions**
Mode: UV
Analytical wavelength: 260 nm. [Note—Depending on the label claim, cells with suitable path lengths may be used.]

**Analysis**
Samples: Standard solution and Sample solution
Calculate the percentage of the labeled amount (Q) of lamotrigine (C_{9}H_{7}Cl_{2}N_{2}) dissolved at each time point i:

$$\text{Result} = \left( \frac{A_i}{A_s} \right) \times C_i \times V \times D \times (1/L) \times 100$$

where:
- $A_i$ = absorbance of the Sample solution
- $A_s$ = absorbance of the Standard solution
- $C_s$ = concentration of the Standard solution (mg/mL)
- $V$ = volume of Medium, 900 mL
- $D$ = dilution factor if needed
- $L$ = label claim (mg/Tablet)

**Tolerances**
For Tablets with 25- or 50-mg label claim: See Table 1.
For Tablets with 100-, 200-, or 250-mg label claim: See Table 2.
For Tablets with 300-mg label claim: See Table 3.

<table>
<thead>
<tr>
<th>Time Point (h)</th>
<th>Amount Dissolved</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NMT 10%</td>
</tr>
<tr>
<td>2</td>
<td>35%–55%</td>
</tr>
<tr>
<td>3</td>
<td>NLT 80%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time Point (h)</th>
<th>Amount Dissolved</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>NMT 10%</td>
</tr>
<tr>
<td>2</td>
<td>NMT 10%</td>
</tr>
<tr>
<td>3</td>
<td>NLT 80%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time Point (h)</th>
<th>Amount Dissolved</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>20%–45%</td>
</tr>
<tr>
<td>2</td>
<td>20%–40%</td>
</tr>
<tr>
<td>3</td>
<td>NLT 80%</td>
</tr>
</tbody>
</table>
Table 3

<table>
<thead>
<tr>
<th>Time Point (i)</th>
<th>Time (h)</th>
<th>Amount Dissolved</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
<td>NMT 10%</td>
</tr>
<tr>
<td>2</td>
<td>6</td>
<td>25%–45%</td>
</tr>
<tr>
<td>3</td>
<td>13</td>
<td>NLT 80%</td>
</tr>
</tbody>
</table>

The percentages of the labeled amount of lamotrigine (C_{9}H_{7}Cl_{2}N_{5}) dissolved at the times specified conform to Dissolution (711), Acceptance Table 2.

Test 2: If the product complies with this test, the labeling indicates that it meets USP Dissolution Test 2.

**Acid stage medium:** 0.01 M hydrochloric acid; 700 mL

**Buffer stage stock medium:** 2.83 g of sodium phosphate monobasic, 1.72 g of sodium hydroxide, and 22.5 g of sodium dodecyl sulfate in 1 L of water

**Buffer stage medium:** Acid stage medium and Buffer stage stock medium (70:20); 900 mL. Adjust with solution A (phosphoric acid in water prepared by diluting 1 mL of phosphoric acid with water to 50 mL) or 0.1 N sodium hydroxide, if necessary, to a pH of 6.8. Record the required volume of solution A or 0.1 N sodium hydroxide for adjustment of pH to 6.8.

**Apparatus 2:** 50 rpm with stationary tablet basket. See Figures 1 and 2.

**Times For Tablets labeled to contain 25 or 50 mg:** 2 h in Acid stage medium; 4, 7, 9, and 15 h in Buffer stage medium

**For Tablets labeled to contain 100, 200, or 300 mg:** 2 h in Acid stage medium; 3, 5, 7, and 12 h in Buffer stage medium

[NOTE—The times in the Buffer stage medium include the time in the Acid stage medium.]

**Procedure:** Run the test with Acid stage medium for 2 h followed by collecting the Acid stage medium sample and replacing it with the same volume of Acid stage medium. Add 200 mL of Buffer stage stock medium to the above solution. If necessary, add either solution A or 0.1 N sodium hydroxide to the solution to reach a pH of 6.8. Continue the testing by drawing samples at the time points specified in Table 4 or Table 5, depending on the label claim. Replace each of the volumes withdrawn with an equal volume of Buffer stage medium.

**Buffer:** Dissolve 2.76 g of sodium phosphate monobasic in 1 L of water. Add 2 mL of triethylamine and adjust with solution A to a pH of 7.0.

**Mobile phase:** Methanol and Buffer (55:45)

**Standard stock solution:** 1.4 mg/mL of USP Lamotrigine RS in methanol

**Acid stage standard solution:** (L/900) mg/mL of USP Lamotrigine RS from Standard stock solution, in Acid stage medium, where L is the label claim in mg/Tablet

**Buffer stage standard solution:** (L/900) mg/mL of USP Lamotrigine RS from Standard stock solution, in Buffer stage medium, where L is the label claim in mg/Tablet

**Acid stage sample solution:** Withdraw a 10.0-mL aliquot, and pass a portion of the solution under test through a suitable filter of 0.45-µm pore size. Replace the 10.0-mL aliquot withdrawn for analysis with a 10.0-mL aliquot of Acid stage medium.

**Buffer stage sample solution:** Withdraw a 10.0-mL aliquot, and pass a portion of the solution under test through a suitable filter of 0.45-µm pore size. Replace the 10.0-mL aliquot withdrawn for analysis with a 10.0-mL aliquot of Buffer stage medium.

Figure 1. Stationary tablet basket.

Figure 2. Drug release stationary tablet basket configuration diagram.
through a suitable filter of 0.45-µm pore size. Replace
the 10.0-mL aliquot withdrawn for analysis with a 10.0-
ml aliquot of Buffer stage medium.

Chromatographic system
(See Chromatography (621), System Suitability.)

Mode: LC
Detector: UV 270 nm
Column: 4.6-mm × 15-cm; 5-µm packing L7
Flow rate: 1 mL/min
Injection volume
For 25-mg Tablets: 80 µL
For 50-mg Tablets: 40 µL
For 100-mg Tablets: 20 µL
For 200- or 300-mg Tablets: 10 µL
Run time: NLT 1.8 times the retention time of
lamotrigine

System suitability
Samples: Acid stage standard solution and Buffer stage
standard solution
Suitability requirements
Tailing factor: NMT 2.0
Relative standard deviation: NMT 2.0%

Analysis
Samples: Acid stage standard solution, Acid stage sample
solution, Buffer stage standard solution, and Buffer stage
sample solution

Calculate the percentage (Qs) of the labeled amount of
lamotrigine (C7H5Cl2N4) dissolved in the Acid stage
medium:

\[
\text{Result}_{\text{A}} = \left( \frac{r_{\text{U}}}{r_{\text{A}}} \right) \times \frac{C_{\text{s}} \times V_{\text{A}} \times (1/L) \times 100}{L}
\]

Calculate the concentration (Cs) of lamotrigine
(C7H5Cl2N4) in the sample withdrawn from the vessel
at each time point (i) during the buffer stage:

\[
\text{Result}_{\text{B}} = \left( \frac{r_{\text{U}}}{r_{\text{i}}} \right) \times C_{\text{i}}
\]

Calculate the percentage of the labeled amount of
lamotrigine (C7H5Cl2N4) dissolved at each time point (i)
during the acid stage or buffer stage (mL):

\[
\text{Result}_{\text{C}} = \left( \frac{(C_{\text{i}} \times V_{\text{B}})}{(C_{\text{i}} \times V_{\text{i}}) \times (1/L) \times 100} + (Q_{\text{A}} \times V_{\text{i}}/V_{\text{B}}) \right)
\]

The percentages of the labeled amount of lamotrigine
(C7H5Cl2N4) dissolved at the times specified conform to
Dissolution (711), Acceptance Table 2.

Test 3: If the product complies with this test, the labeling
indicates that it meets USP Dissolution Test 3.

Acid stage medium: 0.01 M hydrochloric acid; 700 mL
Buffer stage stock medium: 7.8 g of sodium phosphate
tribasic and 22.5 g of sodium dodecyl sulfate in 1 L of
water

Buffer stage medium: Acid stage medium and Buffer
stage stock medium (70:20); 900 mL. Adjust with 2 N
hydrochloric acid TS or 2 N sodium hydroxide TS, if
necessary, to a pH of 6.8.

Apparatus 2: 50 rpm with stationary tablet basket. See
Figures 1 and 2 in Test 2.

Times
For Tablets labeled to contain 25, 50, 100, or 200 mg:
2 h in Acid stage medium; 4, 7, and 14 h in Buffer stage
medium
[NOTE—The times in the Buffer stage medium include
the time in the Acid stage medium.]

Procedure: Run the test with Acid stage medium for 2 h
followed by collecting the Acid stage medium sample and
replacing it with the same volume of Acid stage medium.
Add 200 mL of Buffer stage stock medium to the above
solution. Continue the testing by drawing samples at the
time points specified in Table 6. Replace each of the
volumes withdrawn with an equal volume of the Buffer
stage medium.

Table 4

<table>
<thead>
<tr>
<th>Time Point (h)</th>
<th>Time (h)</th>
<th>Amount Dissolved</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
<td>NMT 10%</td>
</tr>
<tr>
<td>2</td>
<td>4</td>
<td>5%–25%</td>
</tr>
<tr>
<td>3</td>
<td>7</td>
<td>30%–50%</td>
</tr>
<tr>
<td>4</td>
<td>9</td>
<td>50%–70%</td>
</tr>
<tr>
<td>5</td>
<td>15</td>
<td>NLT 80%</td>
</tr>
</tbody>
</table>

Table 5

<table>
<thead>
<tr>
<th>Time Point (h)</th>
<th>Time (h)</th>
<th>Amount Dissolved</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
<td>NMT 10%</td>
</tr>
<tr>
<td>2</td>
<td>3</td>
<td>5%–20%</td>
</tr>
<tr>
<td>3</td>
<td>5</td>
<td>25%–50%</td>
</tr>
<tr>
<td>4</td>
<td>7</td>
<td>50%–70%</td>
</tr>
<tr>
<td>5</td>
<td>12</td>
<td>NLT 80%</td>
</tr>
</tbody>
</table>

© The United States Pharmacopeial Convention All Rights Reserved.
4 Lamotrigine

Buffer: Dissolve 2.72 g of potassium phosphate monobasic in 1 L of water and adjust with dilute phosphoric acid to a pH of 3.7.

Mobile phase: Methanol, acetonitrile, and Buffer (50:15:35)

Standard stock solution: 0.6 mg/mL of USP Lamotrigine RS in methanol. Sonicate to dissolve as needed.

Acid stage standard solution: 0.036 mg/mL of USP Lamotrigine RS from Standard stock solution, in Acid stage medium

Buffer stage standard solution: (L/900) mg/mL of USP Lamotrigine RS from Standard stock solution, in Buffer stage medium, where L is the label claim in mg/Tablet

Acid stage sample solution: Withdraw a 10.0-mL aliquot and pass a portion of the solution under test through a suitable filter of 0.45-µm pore size, discarding the first 5 mL of the filtrate. Replace the 10.0-mL aliquot withdrawn for analysis with a 10.0-mL aliquot of Acid stage medium.

Buffer stage sample solution: Withdraw a 10.0-mL aliquot and pass a portion of the solution under test through a suitable filter of 0.45-µm pore size. Replace the 10.0-mL aliquot withdrawn for analysis with a 10.0-mL aliquot of Buffer stage medium.

Chromatographic system
(See Chromatography (621), System Suitability.)

Mode: LC
Detector: UV 270 nm
Column: 4.6-mm × 25-cm; 5-µm packing L1
Column temperature: 35°C
Flow rate: 1 mL/min
Injection volume: 10 µL
Run time: NLT 1.7 times the retention time of lamotrigine

System suitability
Samples: Acid stage standard solution and Buffer stage standard solution
Suitability requirements
Tailing factor: NMT 2.0
Relative standard deviation: NMT 2.0%

Analysis
Samples: Acid stage standard solution, Acid stage sample solution, Buffer stage standard solution, and Buffer stage sample solution

Calculate the percentage (Qₐ) of the labeled amount of lamotrigine (C₉H₈Cl₂N₄) dissolved in the Acid stage medium:

\[ \text{Result} = \left( \frac{r_i}{r_L} \right) \times C_i \times V_A \times (1/L) \times 100 \]

Where:
- \( r_i \) = peak response from the Acid stage sample solution
- \( r_L \) = peak response from the Acid stage standard solution
- \( C_i \) = concentration of USP Lamotrigine RS in the Acid stage standard solution (mg/mL)
- \( V_A \) = volume of the Acid stage medium, 700 mL
- \( L \) = label claim (mg/Tablet)

Calculate the concentration (C_s) of lamotrigine (C₉H₈Cl₂N₄) in the sample withdrawn from the vessel at each time point \( i \) during the buffer stage:

\[ \text{Result} = \left( \frac{r_i}{r_s} \right) \times C_s \]

Where:
- \( r_i \) = peak response from the Buffer stage sample solution at time point \( i \)
- \( r_s \) = peak response from the Buffer stage standard solution

\[ C_s = \frac{C_i \times V_s}{V_s} \]

Calculate the percentage of the labeled amount of lamotrigine dissolved in the Buffer stage medium:

\[ Q_s = \left( \frac{C_s \times (1/L) \times 100}{V_s} \right) \]

Where:
- \( C_s \) = concentration of lamotrigine in the Buffer stage sample solution withdrawn at time point \( i \) (mg/mL)
- \( V_s \) = volume of the Buffer stage medium, 900 mL
- \( L \) = label claim (mg/Tablet)

Tolerances
For Tablets labeled to contain 25, 50, 100, or 200 mg: See Table 6.

<table>
<thead>
<tr>
<th>Time Point (h)</th>
<th>Time (h)</th>
<th>Amount Dissolved (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
<td>NMT 10</td>
</tr>
<tr>
<td>2</td>
<td>4</td>
<td>NMT 25</td>
</tr>
<tr>
<td>3</td>
<td>7</td>
<td>36–61</td>
</tr>
<tr>
<td>4</td>
<td>14</td>
<td>NLT 85</td>
</tr>
</tbody>
</table>

The percentages of the labeled amount of lamotrigine (C₉H₈Cl₂N₄) dissolved at the times specified conform to Dissolution (711) , Acceptance Table 2.

Test 4: If the product complies with this test, the labeling indicates that it meets USP Dissolution Test 4.

Acid stage medium: 0.01 M hydrochloric acid; 700 mL
Buffer stage stock medium: 7.8 g of sodium phosphate tribasic and 22.5 g of sodium dodecyl sulfate in 1 L of water

Buffer stage medium: Acid stage medium and Buffer stage stock medium (70:20); 900 mL

Apparatus 2: 50 rpm with sinkers

Times
For Tablets labeled to contain 25, 50, 100, 200, or 300 mg: 2 h in Acid stage medium; 9 and 17 h in Buffer stage medium

[NOTE—The times in the Buffer stage medium include the time in the Acid stage medium.]

Procedure: Run the test with Acid stage medium for 2 h followed by collecting the Acid stage medium sample and replacing it with the same volume of Acid stage medium. Add 200 mL of Buffer stage stock medium to the above solution. Continue the testing by drawing samples at the time points specified in Table 7. Replace each of the volumes withdrawn with an equal volume of the Buffer stage medium.

Buffer: Dissolve 4.1 g of potassium phosphate monobasic in 900 mL of water and adjust with dilute phosphoric acid to a pH of 2.0, and then dilute with

© The United States Pharmacopeial Convention All Rights Reserved.
Notice of Intent to Revise
Official: To Be Determined

w ter to 1 L. Add 1.25 g of sodium 1-hexanesulfonate to the solution and mix.

Mobile phase: Acetonitrile and Buffer (25:75)

Acid stage standard stock solution 1: 0.07 mg/mL of USP Lamotrigine RS prepared as follows. Transfer an appropriate amount of USP Lamotrigine RS to a suitable volumetric flask and add 20% of the flask volume of methanol. Sonicate to dissolve and dilute with Acid stage medium to volume. Further dilute this solution with Acid stage medium to obtain a final concentration of 0.07 mg/mL.

Acid stage standard stock solution 2: 0.14 mg/mL of USP Lamotrigine RS prepared as follows. Transfer an appropriate amount of USP Lamotrigine RS to a suitable volumetric flask and add 20% of the flask volume of methanol. Sonicate to dissolve and dilute with Acid stage medium to volume. Further dilute this solution with Acid stage medium to obtain a final concentration of 0.14 mg/mL.

Acid stage standard solution: 0.1 × (L/700) mg/mL of USP Lamotrigine RS either from Acid stage standard stock solution 1 for Tablets labeled to contain 25, 50, 100, and 200 mg, or from Acid stage standard stock solution 2 for Tablets labeled to contain 300 mg, in Acid stage medium, where L is the label claim in mg/Tablet. Pass a portion of the solution through a suitable filter of 0.45-µm pore size, discarding the first 2–3 mL of the filtrate.

Buffer stage standard stock solution 1: 0.55 mg/mL of USP Lamotrigine RS prepared as follows. Transfer an appropriate amount of USP Lamotrigine RS to a suitable volumetric flask and add 10% of the flask volume of methanol. Sonicate to dissolve and dilute with Buffer stage medium to volume.

Buffer stage standard stock solution 2: 1.1 mg/mL of USP Lamotrigine RS either from Buffer stage standard stock solution 1 for Tablets labeled to contain 25, 50, 100, and 200 mg, or from Buffer stage standard stock solution 2 for Tablets labeled to contain 300 mg, in Buffer stage medium, where L is the label claim in mg/Tablet. Pass a portion of the solution through a suitable filter of 0.45-µm pore size, discarding the first 2–3 mL of the filtrate.

Buffer stage standard solution: (L/900) mg/mL of USP Lamotrigine RS either from Buffer stage standard stock solution 1 for Tablets labeled to contain 25, 50, 100, and 200 mg, or from Buffer stage standard stock solution 2 for Tablets labeled to contain 300 mg, in Buffer stage medium, where L is the label claim in mg/Tablet. Pass a portion of the solution through a suitable filter of 0.45-µm pore size, discarding the first 2–3 mL of the filtrate. Acid stage sample solution: Withdraw a 10.0-mL aliquot and pass a portion of the solution under test through a suitable filter of 0.45-µm pore size, discarding the first 2–3 mL of the filtrate. Replace the 10.0-mL aliquot withdrawn for analysis with a 10.0-mL aliquot of Acid stage medium. Pass a portion of the solution through a suitable filter of 0.45-µm pore size, discarding the first 2–3 mL of the filtrate.

Buffer stage sample solution: Withdraw a 10.0-mL aliquot and pass a portion of the solution under test through a suitable filter of 0.45-µm pore size. Replace the 10.0-mL aliquot withdrawn for analysis with a 10.0-mL aliquot of Buffer stage medium. Pass a portion of the solution through a suitable filter of 0.45-µm pore size, discarding the first 2–3 mL of the filtrate.

Chromatographic system
(See Chromatography (621), System Suitability.)

Mode: LC
Detector: UV 270 nm
Column: 4.6-mm × 25-cm; 5-µm packing L7
Column temperature: 60°
Flow rate: 1 mL/min

Injection volume: 10 μL
Run time: NLT 2 times the retention time of lamotrigine

System suitability
Samples: Acid stage standard solution and Buffer stage standard solution

Suitability requirements
Tailing factor: NMT 2.0
Relative standard deviation: NMT 2.0%

Analysis
Samples: Acid stage sample solution, Acid stage sample solution, Buffer stage standard solution, and Buffer stage sample solution

Calculate the percentage (Qr) of the labeled amount of lamotrigine (C3H7Cl2N4) dissolved in the Acid stage medium:

Result = (rU/rS) × C × V × L × 100

Calculate the concentration (C) of lamotrigine (C3H7Cl2N4) in the sample withdrawn from the vessel at each time point (i) during the buffer stage:

Resulti = (rU/rS) × C

Calculate the percentage of the labeled amount of lamotrigine (C3H7Cl2N4) dissolved at each time point (i) during the buffer stage:

Result = [C × V × (1/L) × 100] + (Q × V × L)

Tolerances
For Tablets labeled to contain 25, 50, 100, 200, or 300 mg: See Table 7.
6 Lamotrigine

**Test 5**: If the product complies with this test, the labeling indicates that it meets USP **Dissolution Test 5**.

**Acid stage medium**: 0.01 M hydrochloric acid; 710 mL

**Buffer stage stock medium**: 3.36 g of anhydrous tribasic sodium phosphate and 22.5 g of sodium dodecyl sulfate in 1 L of water

**Buffer stage medium**: Acid stage medium and **Buffer stage stock medium** (70:20); 900 mL. Adjust with hydrochloric acid or 5 N sodium hydroxide TS, if necessary, to a pH of 6.8.

**Apparatus 2**: 50 rpm with sinkers

**Times**

For Tablets labeled to contain 25, 50, 100, or 200 mg: 2 h in Acid stage medium; 4, 7, and 17 h in Buffer stage medium.

(Note—The times in the Buffer stage medium include the time in Acid stage medium.)

**Procedure**: Run the test with Acid stage medium for 2 h followed by collecting the Acid stage medium sample. Add 200 mL of Buffer stage stock medium to this solution. Continue the testing by drawing samples at the time points specified in Table 8.

**Buffer**: Dissolve 3.45 g of monobasic sodium phosphate in 1 L of water, and adjust with phosphoric acid to a pH of 3.3. To this solution, add 5.77 g of sodium dodecyl sulfate, and mix well.

**Mobile phase**: Acetonitrile and **Buffer** (45:55)

**Standard solution**: 0.22 mg/mL of USP Lamotrigine RS in Mobile phase. Sonicate to dissolve as needed.

**Acid stage sample solution**: Withdraw a 10.0-mL aliquot, and pass a portion of the solution under test through a suitable full flow filter of 10-μm pore size.

**Buffer stage sample solution**: Withdraw a 2.5-mL aliquot, and pass a portion of the solution under test through a suitable full flow filter of 10-μm pore size.

**Chromatographic system**

(See Chromatography (621), System Suitability.)

**Mode**: LC

**Detector**: UV 266 nm

**Column**: 4.6-mm x 5-cm; 3.5-μm packing L1

**Column temperature**: 30°C

**Flow rate**: 1 mL/min

**Injection volume**: 10 μL

**Run time**: NLT 1.6 times the retention time of lamotrigine

**System suitability**

**Sample**: Standard solution

**Suitability requirements**

**Tailing factor**: NMT 1.5

**Relative standard deviation**: NMT 2.0%

**Analysis**

**Samples**: Standard solution, Acid stage sample solution, and Buffer stage sample solution

Calculate the percentage (Qi) of the labeled amount of lamotrigine (C6H5Cl3N2) dissolved in the Acid stage medium:

\[
\text{Result} = \left( \frac{r_i}{r_s} \right) \times C_i \times V_A \times \left( \frac{1}{L} \right) \times 100
\]

where

- \(r_i\) = peak response from the Acid stage sample solution
- \(r_s\) = peak response from the Standard solution
- \(C_i\) = concentration of USP Lamotrigine RS in the Standard solution (mg/mL)
- \(V_A\) = volume of the Acid stage medium, 710 mL
- \(L\) = label claim (mg/Tablet)

Calculate the concentration of lamotrigine (C6H5Cl3N2) dissolved at each time point (i) during the buffer stage:

\[
\text{Result}_i = \left( \frac{r_i}{r_s} \right) \times C_i
\]

Calculate the percentage of the labeled amount of lamotrigine (C6H5Cl3N2) dissolved at each time point (i) during the buffer stage:

\[
\text{Result}_i = \left[ C_i \times (V_A \times \left( \frac{1}{L} \right) \times 100 \right] + \left( Q_i \times V_A \times \left( \frac{1}{L} \right) \times \frac{1}{10} \right)
\]

**Tolerances**

For Tablets labeled to contain 25, 50, 100, or 200 mg: See Table 8.

<table>
<thead>
<tr>
<th>Time Point (h)</th>
<th>Time (h)</th>
<th>Amount Dissolved</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
<td>NMT 10</td>
</tr>
<tr>
<td>2</td>
<td>4</td>
<td>10–30</td>
</tr>
<tr>
<td>3</td>
<td>7</td>
<td>35–60</td>
</tr>
<tr>
<td>4</td>
<td>17</td>
<td>NLT 80</td>
</tr>
</tbody>
</table>

The percentages of the labeled amount of lamotrigine (C6H5Cl3N2) dissolved at the times specified conform to **Dissolution (711)**, Acceptance Table 2.

**Test 7**: If the product complies with this test, the labeling indicates that it meets USP **Dissolution Test 7**.

**Acid stage medium**: 0.01 N hydrochloric acid TS; 700 mL, degas by helium sparging before use

© The United States Pharmacopeial Convention All Rights Reserved.
Buffer stage stock medium: 7.8 g of sodium phosphate tribasic in 1 L of water, add 2 mL of sodium hydroxide TS and degas by helium sparging, then add 22.5 g of sodium dodecyl sulfate and mix well. Degas by warming the solution to NMT 50° and bring back to 37° before use.

Buffer stage medium: Acid stage medium and Buffer stage stock medium (70:20), pH 6.8; 900 mL. Adjust with 1 N hydrochloric acid VS or sodium hydroxide TS, if necessary.

Apparatus 1: 75 rpm for Tablets labeled to contain 25, 50, 100, 200, or 300 mg

Apparatus 2: 50 rpm for Tablets labeled to contain 250 mg

Times: 2 h in Acid stage medium; see Table 9 for times in Buffer stage medium. The times in the Buffer stage medium include the time in Acid stage medium.

Procedure: Run the test with Acid stage medium for 2 h followed by collecting the Acid stage sample and replacing it with the same volume of Acid stage medium. Add 200 mL of Buffer stage stock medium to the above solution. Continue the testing by drawing samples at the time points specified in Table 9 without replacing the withdrawn volume.

Buffer: 3.85 g/L of ammonium acetate in water, adjust with acetic acid to a pH of 5.60 ± 0.05

Mobile phase: Acetonitrile and Buffer (32:68)

Standard stock solution: 2.0 mg/mL of USP Lamotrigine RS prepared as follows. Transfer an appropriate amount of USP Lamotrigine RS to a suitable volumetric flask and add 50% flask volume of methanol. Sonicate with occasional swirling for 5 min or until the Reference Standard is completely dissolved. Dilute with Buffer stage medium to volume.

Standard solution: 0.16 mg/mL of USP Lamotrigine RS from Standard stock solution in Buffer stage medium

Acid stage sample solution: Withdraw a suitable volume of the solution under test and replace the withdrawn aliquot with the same volume of Acid stage medium. Pass a portion of the withdrawn solution through a filter of suitable pore size. Discard the first few milliliters of the filtrate.

Buffer stage sample solution: Withdraw a suitable volume of the solution under test and pass a portion of the withdrawn solution through a filter of suitable pore size. Discard the first few milliliters of the filtrate.

Chromatographic system
(See Chromatography (621), System Suitability.)

Mode: LC
Detector: UV 306 nm
Column: 4.6-mm × 15-cm; 5-µm packing L7
Column temperature: 30°
Flow rate: 1 mL/min
Injection volume: 10 µL
Run time: NLT 1.4 times the retention time of lamotrigine

System suitability
Sample: Standard solution
Suitability requirements
Tailing factor: NMT 2.0
Relative standard deviation: NMT 2.0%

Analysis
Samples: Standard solution, Acid stage sample solution, and Buffer stage sample solution

Calculate the percentage (Qₐ) of the labeled amount of lamotrigine (C₉H₇Cl₂N₄) dissolved in the Acid stage medium:

\[ \text{Result} = \left( \frac{r_0}{r_1} \right) \times C_i \times V_a \times \left( \frac{1}{L} \right) \times 100 \]

where:
- \( r_0 \) = peak response from the Acid stage sample solution
- \( r_1 \) = peak response from the Standard solution
- \( C_i \) = concentration of USP Lamotrigine RS in the Standard solution (mg/mL)
- \( V_a \) = volume of the Acid stage medium, 700 mL
- \( L \) = label claim (mg/Tablet)

Calculate the concentration (C) of lamotrigine (C₉H₇Cl₂N₄) in the sample withdrawn from the vessel at each time point (i) during the buffer stage:

\[ \text{Result}_i = \left( \frac{r_0}{r_1} \right) \times C_i \]

\( r_0 \) = peak response from the Buffer stage sample solution at time point i

\( r_1 \) = peak response from the Standard solution

\( C_i \) = concentration of USP Lamotrigine RS in the Standard solution (mg/mL)

Calculate the percentage of the labeled amount of lamotrigine (C₉H₇Cl₂N₄) dissolving at each time point (i) during the buffer stage:

\[ \text{Result}_i = \left( \frac{C_i \times V_a \times (1/L) \times 100}{Q_a \times V_a / V_a} \right) \]

\( V_a \) = volume of the Buffer stage sample solution withdrawn at time point i (mg/mL)

\( Q_a \) = percentage of the labeled amount of lamotrigine dissolved in the Acid stage medium

\( V_r \) = volume of the Sample solution withdrawn at each time point (i)

\( V_a \) = volume of the Acid stage medium, 700 mL

Tolerances: See Table 9.

Table 9

<table>
<thead>
<tr>
<th>Time Point (h)</th>
<th>Time (h)</th>
<th>25 mg/ Tablet (%)</th>
<th>50 mg/ Tablet (%)</th>
<th>100 mg/ Tablet (%)</th>
<th>200 mg/ Tablet (%)</th>
<th>250 mg/ Tablet (%)</th>
<th>300 mg/ Tablet (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
<td>NMT 10</td>
<td>NMT 10</td>
<td>NMT 10</td>
<td>NMT 10</td>
<td>NMT 10</td>
<td>NMT 10</td>
</tr>
<tr>
<td>3</td>
<td>9</td>
<td>45–65</td>
<td>53–73</td>
<td>53–73</td>
<td>53–73</td>
<td>53–73</td>
<td>53–73</td>
</tr>
<tr>
<td>10</td>
<td></td>
<td>NLT 80</td>
<td>NLT 80</td>
<td>NLT 80</td>
<td>NLT 80</td>
<td>NLT 80</td>
<td>NLT 80</td>
</tr>
<tr>
<td>11</td>
<td></td>
<td>NLT 80</td>
<td>NLT 80</td>
<td>NLT 80</td>
<td>NLT 80</td>
<td>NLT 80</td>
<td>NLT 80</td>
</tr>
<tr>
<td>12</td>
<td></td>
<td>NLT 80</td>
<td>NLT 80</td>
<td>NLT 80</td>
<td>NLT 80</td>
<td>NLT 80</td>
<td>NLT 80</td>
</tr>
<tr>
<td>14</td>
<td></td>
<td>NLT 80</td>
<td>NLT 80</td>
<td>NLT 80</td>
<td>NLT 80</td>
<td>NLT 80</td>
<td>NLT 80</td>
</tr>
</tbody>
</table>

© The United States Pharmacopeial Convention All Rights Reserved.
The percentages of the labeled amount of lamotrigine (C₁₇H₂₁Cl₂N₄) dissolved at the times specified conform to Dissolution (711), Acceptance Table 2. ▲ (88 1-Feb-2019)

Test 8: If the product complies with this test, the labeling indicates that it meets USP Dissolution Test 8.

Acid stage medium, Buffer stage stock medium, and Buffer stage medium: Prepare as directed in Dissolution Test 3.

Apparatus 2: 50 rpm
Times: 2 h in Acid stage medium; 6, 11, 17, and 24 h in Buffer stage medium. The times in the Buffer stage medium include the time in the Acid stage medium.

Procedure: Run the test with Acid stage medium for 2 h followed by collecting the Acid stage medium sample. Add 200 mL of Buffer stage stock medium to the above solution. Continue the testing by drawing samples at the time points specified in Table 10.

Buffer: 1.6 g/L each of anhydrous sodium acetate and trichloroacetic acid in water and adjust with either glacial acetic acid or sodium hydroxide TS to a pH of 4.7

Mobile phase: Acetonitrile and Buffer (30:70)

Standard stock solution: 1.1 mg/mL of USP Lamotrigine RS in methanol. Sonicate to dissolve as needed.

Standard solution: (L/900) mg/mL of USP Lamotrigine RS from Standard stock solution, in Buffer stage medium, where L is the label claim in mg/Tablet. Pass the solution through a suitable filter of 0.45-µm pore size. Discard the first few milliliters of the filtrate.

Acid stage sample solution: Withdraw a 1.0-mL aliquot and pass a portion of the solution under test through a suitable filter of 0.45-µm pore size.

Buffer stage sample solution: Withdraw a 1.0-mL aliquot and pass a portion of the solution under test through a suitable filter of 0.45-µm pore size.

Chromatographic system
(See Chromatography (621), System Suitability.)

Mode: LC
Detector: UV 254 nm
Column: 4.6-mm × 25-cm; 5-µm packing L7
Flow rate: 1.2 mL/min
Injection volume
For Tablets labeled to contain 25, 50, 100, or 200 mg: 10 µL
For Tablets labeled to contain 250 or 300 mg: 5 µL
Run time: NLT 1.5 times the retention time of lamotrigine

System suitability
Sample: Standard solution
Suitability requirements
Tailing factor: NMT 2.0
Relative standard deviation: NMT 2.0%

Analysis
Samples: Standard solution, Acid stage sample solution, and Buffer stage sample solution

Calculate the percentage (Q₄) of the labeled amount of lamotrigine (C₁₇H₂₁Cl₂N₄) dissolved in the Acid stage medium:

\[
\text{Result} = \left( \frac{r_i}{r_0} \times C_i \times V_A \times \frac{1}{L} \times 100 \right)
\]

where
- \( r_i \) = peak response from the Acid stage sample solution
- \( r_0 \) = peak response from the Standard solution
- \( C_i \) = concentration of USP Lamotrigine RS in the Standard solution (mg/mL)
- \( V_A \) = volume of the Acid stage medium, 700 mL
- \( L \) = label claim (mg/Tablet)

Calculate the concentration (C) of lamotrigine (C₁₇H₂₁Cl₂N₄) in the sample withdrawn from the vessel at each time point (t) during the buffer stage:

\[
\text{Result} = \left( \frac{r_i/r_0}{C_i} \times C \right)
\]

where
- \( r_i \) = peak response from the Buffer stage sample solution at time point t
- \( r_0 \) = peak response from the Standard solution
- \( C_i \) = concentration of USP Lamotrigine RS in the Standard solution (mg/mL)

Calculate the percentage of the labeled amount of lamotrigine (C₁₇H₂₁Cl₂N₄) dissolved at each time point (t) during the buffer stage:

\[
\text{Result} = \left( \frac{[C_i \times V_A \times (1/L) \times 100]}{Q_i \times V/V_0} \right)
\]

\[
\text{Result} = \left( \frac{[C_i \times V_A \times (1/L) \times 100]}{Q_i \times V/V_0} \right)
\]

\[
\text{Result} = \left( \frac{[C_i \times V_A \times (1/L) \times 100]}{Q_i \times V/V_A} \right)
\]

where
- \( C_i \) = concentration of lamotrigine in the Buffer stage sample solution withdrawn at time point (mg/mL)
- \( V_A \) = volume of the Buffer stage medium, 900 mL
- \( L \) = label claim (mg/Tablet)
- \( Q_i \) = percentage of the labeled amount of lamotrigine dissolved in the Acid stage medium
- \( V_i \) = volume of the sample solution withdrawn at each time point (t) during the acid stage or buffer stage (mL)
- \( V_A \) = volume of the Acid stage medium, 700 mL

Tolerances: See Table 10:

<table>
<thead>
<tr>
<th>Time Point (t)</th>
<th>Time (h)</th>
<th>Amount Dissolved (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
<td>NMT:10</td>
</tr>
<tr>
<td>2</td>
<td>5</td>
<td>14–34</td>
</tr>
<tr>
<td>3</td>
<td>11</td>
<td>42–70</td>
</tr>
<tr>
<td>4</td>
<td>17</td>
<td>NLT:70</td>
</tr>
<tr>
<td>5</td>
<td>24</td>
<td>NLT:85</td>
</tr>
</tbody>
</table>

The percentages of the labeled amount of lamotrigine (C₁₇H₂₁Cl₂N₄) dissolved at the times specified conform to Dissolution (711), Acceptance Table 2. ▲ (88 1-Feb-2019)

- **Uniformity of Dosage Units (905):** Meet the requirements

**Impurities**

Change to read:

- **Organic Impurities**
  Mobile phase, Sample solution, and Chromatographic system: Proceed as directed in the Assay.
  Diluent 1: Acetonitrile, methanol, and 0.1 M hydrochloric acid (10:20:70)
  Diluent 2: Acetonitrile, methanol, and water (10:20:70)
System suitability stock solution: 0.025 mg/mL of USP Lamotrigine Related Compound C RS in Diluent 1
System suitability solution: 1.25 µg/mL of USP Lamotrigine Related Compound C RS and 0.25 mg/mL of USP Lamotrigine RS in Diluent 2 prepared as follows. Transfer a suitable amount of USP Lamotrigine RS to a suitable volumetric flask. Transfer a suitable volume of System suitability stock solution to the flask. Dissolve and dilute with Diluent 2 to volume.

System suitability
Sample: System suitability solution
Suitability requirements
Resolution: NLT 10 between the lamotrigine and lamotrigine related compound C peaks
Signal-to-noise ratio: NLT 100 for lamotrigine related compound C

Analysis
Sample: Sample solution
Calculate the percentage of each degradation product in the portion of Tablets taken:

\[ \text{Result} = \left( \frac{r_U}{r_T} \right) \times 100 \]

- \( r_U \) = response of each impurity from the Sample solution
- \( r_T \) = sum of all of the impurity peak responses and the lamotrigine peak response from the Sample solution

Acceptance criteria: See Table 11. Disregard peaks less than 0.05%.

<table>
<thead>
<tr>
<th>Name</th>
<th>Relative Retention Time</th>
<th>Acceptance Criteria, NMT (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lamotrigine</td>
<td>1.0</td>
<td>—</td>
</tr>
<tr>
<td>Lamotrigine related compound C</td>
<td>1.7</td>
<td>0.3</td>
</tr>
<tr>
<td>Lamotrigine dimer(^a)</td>
<td>6.0</td>
<td>0.2</td>
</tr>
<tr>
<td>Any individual unspecified degradation product</td>
<td>—</td>
<td>0.2</td>
</tr>
<tr>
<td>Total impurities</td>
<td>—</td>
<td>0.5</td>
</tr>
</tbody>
</table>

\(^a\)This is either lamotrigine o-dimer \([N, N'-\text{methylenebis(6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine})]\) or lamotrigine p-dimer \([N, N'-\text{methylenebis(6-(2,3-dichlorophenyl)-1,2,4-triazine-3,5-diamine})]\).

ADDITIONAL REQUIREMENTS
- Packaging and Storage: Preserve in well-closed containers. Store at controlled room temperature.
- Labeling: When more than one Dissolution test is given, the labeling states the Dissolution test used only if Test 1 is not used.
- USP Reference Standards: (11)
  - USP Lamotrigine RS
  - USP Lamotrigine Related Compound C RS
  - 3-Amino-6-(2,3-dichlorophenyl)-1,2,4-triazin-5(4H)-one. \( C_9 H_6 Cl_2 N_4 O \): 257.08